GlassScriptPhysician profile
Paul Julius Spinka
NPI 1457340937
$486.28
in general payments reported to CMS, 2019-2025
9 companies · $133 in 2025
The $133 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $55.19 · 2021: $30.35 · 2022: $31.49 · 2023: $195 · 2024: $40.49 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $369.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $369.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $145.84 | 2021-2023 | Rinvoq |
| Madrigal Pharmaceuticals | $107.90 | 2025 | Rezdiffra |
| Genzyme Corporation | $58.43 | 2023 | |
| Boston Scientific Corporation | $40.49 | 2024 | Orcapod |
| Intercept Pharmaceuticals, INC. | $39.60 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.05 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $25.51 | 2025 | Iqirvo |
| Celgene Corporation | $18.87 | 2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $15.59 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Spinka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.